1,170 reports of this reaction
2.2% of all GLYBURIDE reports
#7 most reported adverse reaction
HYPOGLYCAEMIA is the #7 most commonly reported adverse reaction for GLYBURIDE, manufactured by Cadila Pharmaceuticals Limited. There are 1,170 FDA adverse event reports linking GLYBURIDE to HYPOGLYCAEMIA. This represents approximately 2.2% of all 52,941 adverse event reports for this drug.
Patients taking GLYBURIDE who experience hypoglycaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOGLYCAEMIA is a less commonly reported adverse event for GLYBURIDE, but still significant enough to appear in the safety profile.
In addition to hypoglycaemia, the following adverse reactions have been reported for GLYBURIDE:
The following drugs have also been linked to hypoglycaemia in FDA adverse event reports:
HYPOGLYCAEMIA has been reported as an adverse event in 1,170 FDA reports for GLYBURIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOGLYCAEMIA accounts for approximately 2.2% of all adverse event reports for GLYBURIDE, making it a notable side effect.
If you experience hypoglycaemia while taking GLYBURIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.